Q2 FY2026 · ended Jun 30, 2026 · Revenue $44.23M, -9.5% YoY · Filed Aug 7, 2026
biote Corp. (BTMD) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $44.2 million and a net loss of $6.6 million. Free cash flow was -$3.7 million. As of Jun 30, 2026 it held $11.2 million in cash and investments and $132.1 million in total debt.
Revenue
$44.23M
-9.5% vs year-ago quarter
Net income
$-6.56M
-306.1% vs year-ago quarter
Operating cash flow
$-1.18M
-116.6% vs year-ago quarter
Free cash flow
$-3.73M
-170.7% vs year-ago quarter
EPS
$-0.23
-330.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
58.22M
+2.3% vs prior quarter
Net cash
$-120.97M
Q2 FY2026
Operating margin
8.0%
TTM
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- BTMD (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Irving, TX
- SEC filer status
- Accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1819253
- Former names
- Haymaker Acquisition Corp. III (until May 25, 2022)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $44.2M | $44.9M | $46.4M | $48.0M | $48.9M |
| Operating income | -$3.5M | $3.2M | $6.8M | $8.3M | $10.8M |
| Net income | -$6.6M | $2.3M | $2.0M | $8.2M | $3.2M |
| Diluted EPS | -$0.23 | $0.06 | $0.05 | $0.22 | $0.10 |
| Operating cash flow | -$1.2M | $3.9M | $7.6M | $14.1M | $7.1M |
| Free cash flow | -$3.7M | $3.5M | $6.5M | $13.6M | $5.3M |
| Total assets | $101.7M | $89.0M | $107.6M | $111.3M | $104.8M |
| Total liabilities | $159.9M | $137.0M | $158.0M | $176.8M | $183.6M |
| Stockholders' equity | -$65.8M | -$56.1M | -$58.5M | -$72.8M | -$85.1M |
| Cash and investments | $11.2M | $5.3M | $24.1M | $28.0M | $19.6M |
| Total debt | $132.1M | $104.3M | $106.0M | $107.7M | $109.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Jun 17, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 2, 2026 | May 27, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 18, 2026 | May 12, 2026 |
All 411 biote Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.